|
1
|
Alkis N, Durnali AG, Arslan UY, et al:
Optimal timing of adjuvant treatment in patients with early breast
cancer. Med Oncol. 28:1255–1259. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jha K, Shukla M and Pandey M: Survivin
expression and targeting in breast cancer. Surg Oncol. 21:125–131.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Perou CM, Sorlie T, Eisen MB, et al:
Molecular portraits of human breast tumours. Nature. 406:747–752.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ono M, Tsuda H, Shimizu C, et al:
Tumor-infiltrating lymphocytes are correlated with response to
neoadjuvant chemotherapy in triple-negative breast cancer. Breast
Cancer Res Treat. 132:793–805. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hicks DG, Short SM, Prescott NL, et al:
Breast cancers with brain metastases are more likely to be estrogen
receptor negative, express the basal cytokeratin CK5/6, and
overexpress HER2 or EGFR. Am J Surg Pathol. 30:1097–1104. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oakman C, Viale G and Di Leo A: Management
of triple negative breast cancer. Breast. 19:312–321. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yin WJ, Lu JS, Di GH, et al:
Clinicopathological features of the triple-negative tumors in
Chinese breast cancer patients. Breast Cancer Res Treat.
115:325–333. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin C, Chien SY, Kuo SJ, et al: A 10-year
follow-up of triple-negative breast cancer patients in Taiwan. Jpn
J Clin Oncol. 42:161–167. 2012.PubMed/NCBI
|
|
9
|
Kurebayashi J, Moriya T, Ishida T, et al:
The prevalence of intrinsic subtypes and prognosis in breast cancer
patients of different races. Breast. 16(Suppl 2): S72–S77. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin C, Chien SY, Chen LS, Kuo SJ, Chang TW
and Chen DR: Triple negative breast carcinoma is a prognostic
factor in Taiwanese women. BMC Cancer. 9:1922009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carey LA, Perou CM, Livasy CA, et al:
Race, breast cancer subtypes, and survival in the Carolina Breast
Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rakha EA, El-Sayed ME, Green AR, Lee AH,
et al: Prognostic markers in triple-negative breast cancer. Cancer.
109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dent R, Trudeau M, Pritchard KI, et al:
Triple-negative breast cancer: clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Calza S, Hall P, Auer G, et al: Intrinsic
molecular signature of breast cancer in a population-based cohort
of 412 patients. Breast Cancer Res. 8:R342006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kandel MJ, Stadler Z, Masciari S, et al:
Prevalence of BRCA1 mutations in triple negative breast cancer
(BC). J Clin Oncol. 24:5082006.
|
|
16
|
Haffty BG, Yang Q, Reiss M, et al:
Locoregional relapse and distant metastasis in conservatively
managed triple negative early-stage breast cancer. J Clin Oncol.
24:5652–5657. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang L, Hao C, Dong G and Tong Z:
Analysis of clinical features and outcome of 356 triple-negative
breast cancer patients in China. Breast Care (Basel). 7:13–17.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tischkowitz M, Brunet JS, Begin LR, et al:
Use of immunohistochemical markers can refine prognosis in triple
negative breast cancer. BMC Cancer. 7:1342007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nishimura R and Arima N: Is triple
negative a prognostic factor in breast cancer? Breast Cancer.
15:303–308. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Khan AM, Sabnani I, Tsang P, et al:
Triple-negative early-stage breast cancer in African American
women: A fuel to the fire. J Clin Oncol. 26:110392008.
|
|
21
|
Reis-Filho JS, Milanezi F, Steele D, et
al: Metaplastic breast carcinomas are basal-like tumours.
Histopathology. 49:10–21. 2006. View Article : Google Scholar
|
|
22
|
Abdulkarim BS, Cuartero J, Hanson J,
Deschenes J, Lesniak D and Sabri S: Increased risk of locoregional
recurrence for women with T1-2N0 triple-negative breast cancer
treated with modified radical mastectomy without adjuvant radiation
therapy compared with breast-conserving therapy. J Clin Oncol.
29:2852–2858. 2011. View Article : Google Scholar
|
|
23
|
Hernandez-Aya LF, Chavez-Macgregor M, Lei
X, et al: Nodal status and clinical outcomes in a large cohort of
patients with triple-negative breast cancer. J Clin Oncol.
29:2628–2634. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Minn AJ, Gupta GP, Siegel PM, et al: Genes
that mediate breast cancer metastasis to lung. Nature. 436:518–524.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bertucci F, Finetti P, Cervera N, et al:
Gene expression profiling shows medullary breast cancer is a
subgroup of basal breast cancers. Cancer Res. 66:4636–4644. 2006.
View Article : Google Scholar
|
|
26
|
Fadare O, Wang SA and Hileeto D: The
expression of cytokeratin 5/6 in invasive lobular carcinoma of the
breast: evidence of a basal-like subset? Hum Pathol. 39:331–336.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Carey LA, Dees EC, Sawyer L, et al: The
triple negative paradox: primary tumor chemosensitivity of breast
cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kaplan HG, Malmgren JA and Atwood M: T1N0
triple negative breast cancer: risk of recurrence and adjuvant
chemotherapy. Breast J. 15:454–460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, Liu
GY, Wu J, Shen KW, Han QX, Shen ZZ and Shao ZM: Clinicopathological
features of the triple-negative tumors in Chinese breast cancer
patients. Breast Cancer Res Treat. 115:325–333. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thike AA, Cheok PY, Jara-Lazaro AR, Tan B,
Tan P and Tan PH: Triple-negative breast cancer:
clinicopathological characteristics and relationship with
basal-like breast cancer. Mod Pathol. 23:123–133. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shah SN, Cope L, Poh W, et al: HMGA1: a
master regulator of tumor progression in triple-negative breast
cancer cells. PLoS One. 8:e634192013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maire V, Baldeyron C, Richardson M, et al:
TTK/hMPS1 is an attractive therapeutic target for triple-negative
breast cancer. PLoS One. 8:e637122013. View Article : Google Scholar : PubMed/NCBI
|
